Table 4.

 Proportion of patients with clinical symptoms of suicidality and self harm by treatment group and assessment according to allocated treatment with selective serotonin reuptake inhibitors (SSRIs) alone or in combination with cognitive behaviour therapy (CBT)

	SSRI			CBT plus SSRI		Time-treatment interaction* (95% CI); P value	Treatment effect*† (95% CI); P value
	Frequency (%)	No of patients		Frequency (%)	No of patients
Thoughts (recurrent thoughts of death)
Baseline	48 (46.6)	103		50 (47.6)	105	1.030 (0.97 to 1.10); 0.34	0.867 (0.38 to 1.98); 0.74
6 weeks	23 (23.5)	98		17 (17.3)	98
12 weeks	17 (17.0)	100		19 (18.8)	101
28 weeks	11 (11.7)	94		15 (15.3)	98
Ideation (often thinks of suicide and has thought of specific method)
Baseline	44 (42.7)	103		40 (38.1)	105	1.052 (0.99 to 1.12); 0.13	0.908 (0.39 to 2.11); 0.82
6 weeks	18 (18.4)	98		10 (10.2)	98
12 weeks	13 (13.0)	100		16 (15.8)	101
28 weeks	9 (9.6)	94		13 (13.3)	98
Acts (has attempted suicide with definite suicidal intent)
Baseline	21 (20.4)	103		13 (12.4)	105	1.023 (0.95 to 1.10); 0.54	0.856 (0.38 to 1.94); 0.71
6 weeks	9 (9.2)	98		5 (5.1)	98
12 weeks	8 (8.0)	100		7 (6.9)	101
28 weeks	6 (6.4)	94		7 (7.1)	98
Medical lethality (considerable harm from attempted suicide such as brief unconsciousness)
Baseline	4 (3.9)	103		3 (2.9)	105	0.955 (0.84 to 1.08); 0.47	2.446 (0.67 to 8.92); 0.18
6 weeks	1 (1.0)	98		2 (2.0)	98
12 weeks	1 (1.0)	100		3 (3.0)	101
28 weeks	2 (2.1)	94		3 (3.1)	98
Self harm (non-suicidal)‡
Baseline	23 (22.3)	103		30 (28.6)	105	0.939 (0.88 to 1.01); 0.070	2.681 (1.15 to 6.26); 0.023
6 weeks	5 (5.1)	98		18 (18.4)	98
12 weeks	11 (11.0)	100		15 (14.9)	101
28 weeks	9 (9.6)	94		12 (12.2)	98

*Adjusted for time, sex, age, site, behavioural disorder, children's global assessment scale, and baseline value of outcome measure.

†Refers to estimated mean across three follow-up time points.

‡Frequent (≥4 times/year) or has caused serious injury to self (such as burn with scarring, broken bone).